Evasion of COPD in smokers: At what price?

European Respiratory Journal

Volumn 39, Issue 6, 2012, Pages 1298-1303

  Cosio, Manuel G ^a,b   Saetta, Marina ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer; Chronic obstructive pulmonary disease; Immune response; Monocyte macrophage

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; DISEASE SEVERITY; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOGENESIS; LUNG INJURY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REGULON; REVIEW; SMOKING; SUPPRESSOR CELL;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; LUNG; MACROPHAGES, ALVEOLAR; MICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; T-LYMPHOCYTES, REGULATORY;

EID: 84861870244     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00135711     Document Type: Review

References (51)

1. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
2. Brent L. The 50th anniversary of the discovery of immunologic tolerance. N Engl J Med 2003; 349: 1381-1383.
3. Finkelstein R, Fraser RS, Ghezzo H, et al. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995; 152: 1666-1672.
4. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
5. Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010; 11: 14-20.
6. Mueller D. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010; 11: 21-27.
7. Torres-Aguilar H, Blank M, Jara LJ, et al. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010; 10: 8-17.
8. Guerassimov A, Takubo Y, Turcotte A, et al. The development of emphysema in cigarette smoke exposed mice is strain dependent. Am J Respir Crit Care Med 2004; 170: 974-980.
9. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13 2002; 323-340.
10. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol 2005; 6: 1182-1189.
11. Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol 2010; 10: 24-35.
12. Henson P. Dampening inflammation. Nat Immunol 2005; 6: 1179-1181.
13. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137.
14. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9: 239-244.
15. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004; 114: 1198-1208.
16. Lane N, Robins RA, Corne J, et al. Regulation in chronic obstructive lung disease: the role of regulatory T-cells and Th17 cells. Clin Sci 2010; 119: 75-86.
17. Smyth LJC, Starkey C, Vestbo J, et al. CD4-regulatory cells in COPD patients. Chest 2007; 132: 156-163.
18. Plumb J, Smyth LJC, Adams HR, et al. Increased T-regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir J 2009; 34: 89-94.
19. Barcelo B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory Tlymphocyte response to tobacco smoking. Eur Respir J 2008; 31: 555-562.
20. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
21. Isajevs S, Taivans I, Strazda G, et al. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J 2009; 33: 61-67.
22. Pons J, Sauleda J, Ferrer JM, et al. Blunted cdT-lymphocyte response in chronic obstructive pulmonary disease. Eur Respir J 2005; 25: 441-446.
23. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896.
24. Shaykhiev R, Krause A, Salit J, et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of COPD. J Immunol 2009; 183: 2867-2883.
25. Woodruff P. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 2005; 172: 1383-1392.
26. Dolcetti L, Marigo I, Mantelli B, et al. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008; 267: 216-225.
27. Diaz-Montero M, Labib Salem M, Nishimura M, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
28. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67: 9518-9527.
29. Bunt SK, Clements VK, Hanson EM, et al. Inflammation enhances myeloid-derived suppressor cell crosstalk by signaling through Toll-like receptor 4. J Leukocyte Biol 2009; 85: 996-1004.
30. Gabrilovich DI, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
31. Ezernitchi AV, Vaknin I, Cohen-Daniel L, et al. TCRf down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006; 177: 4763-4772.
32. Sopori M. Effects of cigarette smoke on the immune system. Nature Rev Immunol 2002; 2: 372-377.
33. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nature Rev Immunol 2009; 9: 377-384.
34. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis 1989; 139: 194-198.
35. Mian MF, Lauzon NM, Stämpfli MR, et al. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 2008; 83: 774-784.
36. Berenson CS, Garlipp MA, Grove LJ, et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006; 194: 1375-1384.
37. Hodge S, Hodge G, Ahern J, et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007; 37: 748-755.
38. Drannik AG, Pouladi MA, Robbins CS, et al. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2004; 170: 1164-1171.
39. Gaschler GJ, Zavitz CC, Bauer CM, et al. Cigarette smoke exposure attenuates cytokine production by mouse alveolar macrophages. Am J Respir Cell Mol Biol 2008; 38: 218-226.
40. Harrigan JA, Vezina CM, McGarrigle BP, et al. DNA adduct formation in precision?cut rat liver and lung slices exposed to benzo[a]pyrene. Toxicol Sci 2004; 77: 307-314.
41. 2+ stores. J Pharmacol Exp Ther 2000; 293: 166-171.
42. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-1480.
43. Tockman MS, Anthonisen NR, Wright EC, et al. Airway obstruction and the risk for lung cancer. Ann Intern Med 1987; 106: 512-518.
44. Baraldo S, Saetta M, Cosio MG. For whom the "alarm" tolls: how we sense the danger of cigarette smoke and react to it. Am J Respir Crit Care Med 2010; 181: 879-880.
45. Ferhani N, Letuve S, Kozhich A, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 917-927.
46. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
47. Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol 2010; 6: 511-519.
48. Gutierrez-Dalmau A, Campistol, JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007; 67: 1167-1198.
49. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
50. Hemminki K, Liu X, Ji J, et al. Subsequent COPD and lung cancer in patients with autoimmune disease. Eur Respir J 2011; 37: 463-464.
51. Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with COPD: incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913-919.